Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.7B | $30.0B | $30.6B | $28.9B | $30.1B | $31.7B | $31.2B | $32.4B | $33.5B | $36.4B |
| Revenue growth | — | 0.8% | 2.0% | -5.4% | 4.2% | 5.2% | -1.4% | 3.6% | 3.6% | 8.4% |
| Gross profit | $20.4B | $20.9B | — | — | — | — | — | — | — | — |
| Gross margin | 68.7% | 69.8% | — | — | — | — | — | — | — | — |
| Operating income | $5.38B | $6.64B | $6.27B | $4.79B | $4.48B | $5.75B | $5.49B | $5.14B | $5.96B | $6.47B |
| Operating margin | 18.1% | 22.2% | 20.5% | 16.6% | 14.9% | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Net income | $4.03B | $3.10B | $4.63B | $4.79B | $3.61B | $5.04B | $3.76B | $3.68B | $4.66B | $4.80B |
| Net margin | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| EPS (diluted) | $2.89 | $2.27 | $3.41 | $3.54 | $2.66 | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.88B | $4.68B | $7.01B | $7.23B | $6.24B | $7.35B | $6.04B | $6.79B | $7.04B | $7.33B |
| Capital expenditures | $1.25B | $1.07B | $1.13B | $1.21B | $1.35B | $1.37B | $1.46B | $1.59B | $1.86B | $1.90B |
| Free cash flow | $5.63B | $3.62B | $5.87B | $6.02B | $4.88B | $5.98B | $4.58B | $5.20B | $5.18B | $5.43B |
| Share buybacks | $3.54B | $2.17B | $2.88B | $1.33B | $652M | $2.54B | $645M | $2.14B | $3.23B | $1.03B |
| Dividends paid | $2.38B | $2.49B | $2.69B | $2.89B | $3.12B | $3.38B | $3.62B | $3.67B | $3.59B | $3.64B |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.97B | $3.67B | $4.39B | $4.14B | $3.59B | $3.71B | $1.54B | $1.28B | $2.22B | $1.95B |
| Total assets | $99.9B | $91.4B | $89.7B | $90.7B | $93.1B | $91.0B | $90.9B | $90.0B | $91.7B | $93.0B |
| Total liabilities | $49.5B | $40.6B | $39.5B | $39.8B | $41.5B | $38.3B | $39.3B | $39.6B | $43.4B | $43.0B |
| Long-term debt | $25.9B | $23.7B | $24.6B | $22.1B | — | — | — | — | — | — |
| Shareholders' equity | $50.2B | $50.7B | $50.1B | $50.7B | $51.4B | $52.6B | $51.5B | $50.2B | $48.0B | $49.5B |
| Retained earnings | $23.3B | $24.4B | $26.3B | $28.1B | $28.6B | $30.3B | $30.4B | $30.4B | $31.5B | $32.6B |
| Shares (wtd avg diluted) | 1.39B | 1.37B | 1.36B | 1.35B | 1.35B | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B |
Every figure is extracted from Medtronic plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.